Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli

During the last decade, the efforts to combat multidrug-resistant (MDR) microorganisms mainly focused on gram-positive bacteria, namely, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. While a large number of hospitals have implemented more rigorous infection

[1]  A. Levin,et al.  Nosocomial Infection With Cephalosporin-Resistant Klebsiella pneumoniae Is Not Associated With Increased Mortality , 2006, Infection Control & Hospital Epidemiology.

[2]  Yehuda Carmeli,et al.  Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae , 2006, Antimicrobial Agents and Chemotherapy.

[3]  K. Ko,et al.  Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. , 2007, The Journal of antimicrobial chemotherapy.

[4]  N. Woodford,et al.  The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. , 2006, Trends in microbiology.

[5]  Y. Carmeli,et al.  Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting , 2005, Current opinion in infectious diseases.

[6]  I. Petersen,et al.  Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. , 2007, The Journal of infection.

[7]  P. Turner,et al.  The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  R. Sood,et al.  Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. , 2004, American journal of infection control.

[9]  Ronald N. Jones,et al.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Ronald N. Jones,et al.  Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). , 2002, Diagnostic microbiology and infectious disease.

[11]  S. Pitlik,et al.  Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997–2002 , 2005, Journal of Hospital Infection.

[12]  H. Goossens.  Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  J. Gerberding,et al.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. , 2006, MMWR. Morbidity and mortality weekly report.

[14]  Y. Carmeli,et al.  The Case-Case-Control Study Design: Addressing the Limitations of Risk Factor Studies for Antimicrobial Resistance , 2005, Infection Control & Hospital Epidemiology.

[15]  K. Laupland,et al.  Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. , 2005, The Journal of antimicrobial chemotherapy.

[16]  M. Falagas,et al.  The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. , 2006, Journal of medical microbiology.

[17]  Y. Carmeli,et al.  High Levels of Antimicrobial Coresistance among Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae , 2005, Antimicrobial Agents and Chemotherapy.

[18]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.

[19]  Z. Samra,et al.  First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. , 2007, Diagnostic microbiology and infectious disease.

[20]  P. Bradford,et al.  Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. , 2004, International journal of antimicrobial agents.

[21]  J. Quinn,et al.  First Detection of the Plasmid-Mediated Class A Carbapenemase KPC-2 in Clinical Isolates of Klebsiella pneumoniae from South America , 2006, Antimicrobial Agents and Chemotherapy.

[22]  R. Bonomo,et al.  The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! , 2005, Current opinion in microbiology.

[23]  N. Singh,et al.  Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. , 2007, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[24]  Neil Woodford,et al.  The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter , 2006 .

[25]  R. Bonomo,et al.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  G. Fadda,et al.  Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment , 2007, Antimicrobial Agents and Chemotherapy.

[27]  D. Paterson,et al.  A step closer to extreme drug resistance (XDR) in gram-negative bacilli. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[29]  E. Rubinstein,et al.  Tigecycline , 2012, Drugs.

[30]  J. Craig,et al.  Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. , 2007, The Journal of hospital infection.

[31]  J. Karlowsky,et al.  Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001 , 2003, Antimicrobial Agents and Chemotherapy.

[32]  D. Livermore.  Tigecycline: what is it, and where should it be used? , 2005, The Journal of antimicrobial chemotherapy.

[33]  A. Yamaguchi,et al.  Effects of Efflux Transporter Genes on Susceptibility of Escherichia coli to Tigecycline (GAR-936) , 2004, Antimicrobial Agents and Chemotherapy.

[34]  A. Sundsfjord,et al.  Effects of Phenotype and Genotype on Methods for Detection of Extended-Spectrum-β-Lactamase-Producing Clinical Isolates of Escherichia coli and Klebsiella pneumoniae in Norway , 2006, Journal of Clinical Microbiology.

[35]  F. Baquero,et al.  Antibiotic Coresistance in Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline , 2006, Antimicrobial Agents and Chemotherapy.

[36]  F. Baquero,et al.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). , 2006, The Journal of antimicrobial chemotherapy.

[37]  N. Woodford,et al.  Multiresistant acinetobacter in the UK: how big a threat? , 2004, The Journal of hospital infection.

[38]  S. Amyes,et al.  OXA β-lactamases in Acinetobacter: the story so far , 2006 .

[39]  吉田 仁美,et al.  Strength in Diversity , 2019, Bridging Communities through Socially Engaged Art.

[40]  S. Unal,et al.  Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. , 2005, Diagnostic microbiology and infectious disease.

[41]  W. Bilker,et al.  Risk Factors for and Outcomes of Bloodstream Infection Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species in Children , 2005, Pediatrics.

[42]  S. Amyes,et al.  OXA (beta)-lactamases in Acinetobacter: the story so far. , 2006, The Journal of antimicrobial chemotherapy.

[43]  C L Emery,et al.  Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center , 1997, Journal of clinical microbiology.

[44]  I. Kobayashi,et al.  An epidemiological study of the susceptibility and frequency of multiple-drug-resistant strains of Pseudomonas aeruginosa isolated at medical institutes nationwide in Japan , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[45]  Timothy R. Walsh,et al.  Metallo-β-Lactamases: the Quiet before the Storm? , 2005, Clinical Microbiology Reviews.

[46]  Y. Carmeli,et al.  Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in Israel , 2006, Antimicrobial Agents and Chemotherapy.

[47]  D. Paterson,et al.  Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. , 2006, The Journal of antimicrobial chemotherapy.

[48]  Y. Carmeli,et al.  Emergence of KPC-2 and KPC-3 in Carbapenem-Resistant Klebsiella pneumoniae Strains in an Israeli Hospital , 2007, Antimicrobial Agents and Chemotherapy.

[49]  D. Landman,et al.  Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. , 2007, The Journal of antimicrobial chemotherapy.

[50]  J. Woo,et al.  Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. , 2002, The Journal of hospital infection.

[51]  The Cost of Antibiotic Resistance: Effect of Resistance Among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on Length of Hospital Stay , 2002, Infection Control & Hospital Epidemiology.

[52]  David L Paterson.  Resistance in gram-negative bacteria: enterobacteriaceae. , 2006, The American journal of medicine.

[53]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[54]  V. Miriagou,et al.  VIM-1 Metallo-β-Lactamase-Producing Klebsiella pneumoniae Strains in Greek Hospitals , 2003, Journal of Clinical Microbiology.

[55]  J. Daurès,et al.  Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. , 2004, The Journal of hospital infection.

[56]  P. Bradford,et al.  Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae , 2005, Antimicrobial Agents and Chemotherapy.

[57]  M. Oh,et al.  Risk Factors for and Clinical Outcomes of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae , 2004, Infection Control & Hospital Epidemiology.

[58]  Yasuaki Yamada,et al.  Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  P. Bradford.  Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[60]  P. Nordmann,et al.  Metallo-beta-lactamases: the quiet before the storm? , 2005, Clinical microbiology reviews.

[61]  D. Nicolau,et al.  Impact of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species on Clinical Outcomes and Hospital Costs: A Matched Cohort Study , 2006, Infection Control & Hospital Epidemiology.

[62]  M. Falagas,et al.  Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria , 2005, BMC infectious diseases.

[63]  D. Anderson,et al.  Predictors of Mortality in Patients with Bloodstream Infection Due to Ceftazidime-Resistant Klebsiella pneumoniae , 2006, Antimicrobial Agents and Chemotherapy.

[64]  Ronald N. Jones,et al.  Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[65]  Ronald N. Jones,et al.  Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. , 2006, Diagnostic microbiology and infectious disease.

[66]  M. Lam,et al.  Risk Factors and Outcomes of Extended-Spectrum Beta-Lactamase-Producing E. Coli Peritonitis in Capd Patients , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[67]  Ronald N. Jones,et al.  Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). , 2005, Diagnostic microbiology and infectious disease.

[68]  F. Baas,et al.  Mechanisms of multidrug-resistance , 1994 .

[69]  S. Dantas,et al.  Impact of Antibiotic-Resistant Pathogens Colonizing the Respiratory Secretions of Patients in an Extended-Care Area of the Emergency Department , 2003, Infection Control & Hospital Epidemiology.

[70]  L. Goldani,et al.  The influence of metallo-β-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections , 2006 .

[71]  C. Schultsz,et al.  Endemic Multidrug-Resistant Pseudomonas aeruginosa in Critically Ill Patients , 2004, Infection Control & Hospital Epidemiology.

[72]  Y. Carmeli,et al.  Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  A. Evangelista,et al.  Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  H. Sun,et al.  Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. , 2004, The Journal of hospital infection.

[75]  Matthew E Falagas,et al.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  Yehuda Carmeli,et al.  Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact , 2006, Antimicrobial Agents and Chemotherapy.

[77]  D. Hospenthal,et al.  Treatment of multidrug resistant Acinetobacter , 2005, Current opinion in infectious diseases.

[78]  R. Jones,et al.  Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[79]  W. Bilker,et al.  Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. , 2006, The American journal of medicine.

[80]  G. Fadda,et al.  Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome , 2006, Antimicrobial Agents and Chemotherapy.

[81]  Ronald N. Jones,et al.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). , 2004, Diagnostic microbiology and infectious disease.

[82]  J. Bartlett,et al.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  D. Paterson,et al.  Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[84]  Y. Chou,et al.  Clinical features of nosocomial infections by extended‐spectrum β‐lactamase‐producing Enterobacteriaceae in neonatal intensive care units , 2005, Acta paediatrica.

[85]  M. Oh,et al.  Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. , 2005, Microbial drug resistance.

[86]  T. Wong,et al.  Multi-resistant Acinetobacter baumannii on a burns unit--clinical risk factors and prognosis. , 2002, Burns : journal of the International Society for Burn Injuries.

[87]  D. Church,et al.  Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. , 2005, The Journal of infectious diseases.

[88]  A. MacGowan,et al.  EUCAST technical note on tigecycline. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[89]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  G. Schito.  The importance of the development of antibiotic resistance in Staphylococcus aureus. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.